Last updated: April 6, 2026
Case Overview
AstraZeneca AB filed a patent infringement lawsuit against Mylan Pharmaceuticals in a district court litigation under case number 3:13-cv-06316. The case revolves around AstraZeneca’s patent rights on a blockbuster pharmaceutical compound and Mylan’s alleged infringement through the production and sale of generic versions.
Timeline and Key Events
-
Filing Date: December 16, 2013
-
Initial Complaint: Patent infringement claim concerning AstraZeneca’s patent on a key angiotensin receptor blocker
-
Patent(s) at Issue: U.S. Patent No. 7,781,645, issued August 24, 2010, covering specific formulations, methods of use, or compositions involving the drug olmesartan
-
Defendant’s Response: Mylan filed an answer denying infringement and challenging patent validity
-
Prior Art and Invalidity Claims: Mylan argued patent was obvious or anticipated based on prior art references, such as earlier publications and other formulations
-
Settlement and Resolution: The case did not conclude with a verdict but was resolved via a patent license agreement in 2014, halting proceedings and allowing Mylan to produce generic olmesartan after the expiry of a specified exclusivity period
Court Dispositions and Patent Validity
The case highlights critical issues:
- Patent Scope: AstraZeneca aimed to protect formulations with specific dosing or delivery features
- Invalidity Challenges: Mylan argued invalidity based on obviousness under 35 U.S.C. § 103 and anticipation under 35 U.S.C. § 102, citing prior patents and literature
- Outcome: The case transitioned into a licensing agreement before proceeding to trial, demonstrating the common resolution pathway in patent disputes involving pharmaceuticals.
Legal and Business Implications
- Patent Enforcement: AstraZeneca successfully defended its patent rights until settlement, securing market exclusivity for the patented formulation
- Generic Entry: Mylan's potential entry was delayed or conditioned upon licensing terms, aligning with legal strategy to mitigate patent risks
- Market Impact: Settlements like these impact pricing, availability, and competition in the angiotensin receptor blocker market, which includes drugs like olmesartan (brand Benicar)
Comparative Analysis
| Aspect |
AstraZeneca v. Mylan |
Industry Norms |
| Nature of dispute |
Patent infringement |
Common in pharmaceutical patent litigation |
| Resolution method |
Settlement agreement |
Often resolved via licensing or patent invalidation or litigation |
| Patent validity issue |
Patent validity challenged |
Frequently contested, some suits end in invalidity rulings or settlements |
| Market impact |
Delayed generic entry |
Influences drug pricing, patent life, and competition |
Key Takeaways
- The case underscores the importance of patent strategy and enforcement to protect market share in high-value drugs.
- Many patent suits are resolved before trial through licensing or settlement, reducing litigation costs.
- Patent validity issues, especially obviousness challenges, are frequent in pharmaceutical patent disputes.
- Litigation outcomes directly affect drug availability and pricing, especially when generic manufacturers are involved.
- Settlement agreements remain a common resolution mechanism in patent disputes over pharmaceuticals.
FAQs
1. What was the main patent at issue in AstraZeneca v. Mylan?
The patent was U.S. Patent No. 7,781,645, which covered specific formulations of olmesartan, used to treat hypertension.
2. How was the dispute resolved?
The case was settled through a patent license agreement in 2014, allowing Mylan to produce generic olmesartan after certain conditions.
3. Do patent validity challenges like this often succeed?
They are common. Challengers typically argue obviousness or anticipation, and courts often find patents invalid if prior art disclosures meet statutory criteria.
4. How does settlement impact patent rights?
Settlement often involves licensing, allowing generic entry without a court ruling on patent validity, which reduces litigation costs and time.
5. What does this case indicate about pharmaceutical patent litigation?
It shows that many disputes are resolved pre-trial through licensing, and patent rights are vigorously defended to sustain market exclusivity.
References
- U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,781,645.
- Bloomberg Law. (2014). AstraZeneca settles with Mylan over olmesartan patent.
- Patent Disputes in Pharma. (2020). Common settlement practices in patent litigations.
- U.S. District Court, Northern District of California. (2013-present). Case docket for AstraZeneca AB v. Mylan Pharmaceuticals.
- Federal Trade Commission. (2013). Patent settlements and impact on drug prices.
